What was known before {#section19-2054358120906974}
=====================

Increased aortic stiffness as measured by carotid-femoral pulse wave velocity (cf-PWV) is a risk factor for cardiovascular events and all-cause mortality in end-stage renal disease (ESRD). Several pharmacologic interventions have been developed to slow the progression of aortic stiffness in ESRD, and cf-PWV has been proposed to monitor responses.

What this adds {#section20-2054358120906974}
==============

Most pharmacologic interventions that target aortic stiffness in ESRD are associated with mixed effects on reducing cf-PWV, with some strategies such as control of blood pressure with calcium-channel blockers suggesting potential benefit. Evidence, however, is insufficient to recommend their routine use for this purpose and further well-designed studies are necessary to determine the clinical relevance of these associations.

In ESRD, increased aortic stiffness is recognized as a risk factor for cardiovascular events and all-cause mortality.^[@bibr1-2054358120906974],[@bibr2-2054358120906974]^ Increased arterial stiffness leads to an earlier return of peripherally reflected pressure waves, resulting in increased cardiac workload due to augmentation of the central pulse pressure.^[@bibr3-2054358120906974],[@bibr4-2054358120906974]^ Although several non-invasive methods exist to evaluate aortic stiffness,^[@bibr5-2054358120906974]^ cf-PWV has been established as an independent marker associated with non-fatal cardiovascular events and all-cause mortality in ESRD.^[@bibr2-2054358120906974]^ As atherosclerosis, increased blood pressure, alterations in bone mineral metabolism and vascular calcification are prominent during the transition from chronic kidney disease to ESRD, these mechanisms have been associated with the accelerated progression of aortic stiffness that occurs in chronic dialysis patients.^[@bibr6-2054358120906974]^ To minimize the deleterious effects of these risk factors, several interventions have been proposed and cf-PWV has been used to monitor responses. In a previous systematic review and meta-analysis, we reported the effects of non-pharmacologic-based interventions on reducing cf-PWV and systolic blood pressure (SBP).^[@bibr7-2054358120906974]^ In this investigation, we systematically analyzed existing randomized and non-randomized studies that assessed pharmacologic interventions aimed at control of hypertension (renin-angiotensin system inhibitors, calcium-channel blockers), bone mineral imbalance (vitamin D analogues, calcimimetics, and phosphate binders), serum homocysteine levels, and anemia correction (recombinant human erythropoietin) and without any restriction on the type of comparator, in patients (≥18 years old) with ESRD of any duration and receiving or not any renal replacement therapy (hemodialysis and peritoneal dialysis) with the purpose of evaluating their effects on cf-PWV. Second, we evaluated the impact on SBP.

Materials and Methods {#section21-2054358120906974}
=====================

Data Sources and Search Strategy {#section22-2054358120906974}
--------------------------------

The review was conducted in accordance with the Cochrane Collaboration methods, Systematic Reviews standards,^[@bibr8-2054358120906974]^ and PRISMA guidelines.^[@bibr9-2054358120906974]^ The study protocol has been published^[@bibr10-2054358120906974]^ and registered in PROSPERO ([www.crd.york.ac.uk/prospero](http://www.crd.york.ac.uk/prospero); CRD42016033463). A comprehensive, systematic search strategy was implemented using MEDLINE, EMBASE, Cochrane Central databases, the Cochrane Central Register of Controlled Trials, Cochrane Methodology Register, Health Technology Assessment Database, CADTH's "Grey Matters Light," OVID, EBM reviews, and gray literature for studies published between January 1965 and May 2019. We accessed material and research produced by organizations outside of academic publishing journals including the "Grey Matters Light" of the Canadian Agency for Drugs and Technologies in Health. A detailed description of the reviewing methods including study screening, inclusion and exclusion criteria, and assessment of the quality of evidence has been published elsewhere.^[@bibr7-2054358120906974]^ Two independent reviewers evaluated quality according to study design. The risk of bias in randomized studies was evaluated with the Cochrane Collaboration tool.^[@bibr8-2054358120906974]^ For non-randomized studies, we used the "SIGN50" (cohort studies)^[@bibr11-2054358120906974]^ and the NIH Quality Assessment Tool (cross-sectional studies and before-and-after single cohort designs).^[@bibr12-2054358120906974]^ The original search strategy aimed to capture both pharmacologic and non-pharmacologic interventions ([Appendix 1](http://journals.sagepub.com/doi/suppl/10.1177/2054358120906974)).

Inclusion and Exclusion Criteria {#section23-2054358120906974}
--------------------------------

We included adults (≥18 years old) with end-stage renal disease (ESRD) defined as stage-5 chronic kidney disease (estimated glomerular filtration rate \[e-GFR\] \< 15 mL/min/1.73 m^2^) of any duration and receiving or not renal replacement therapy. Studies involving pharmacologic interventions in adults with kidney transplantation as the current modality of renal replacement were excluded; in a separate study, we have reported the impact of non-pharmacologic interventions, including kidney transplantation, on cf-PWV in ESRD.^[@bibr7-2054358120906974]^ This study included adults with ESRD participating in randomized control trials and non-randomized studies (cohort, case-control, cross-sectional, and single cohorts with before-and-after design) with at least 10 participants, involving a pharmacologic intervention whose effect was assessed by cf-PWV.

Study Screening, Review, and Abstraction {#section24-2054358120906974}
----------------------------------------

All abstracts and titles were screened by 2 independent reviewers using pre-specified criteria. Abstract selection was restricted to those published in English, French, Italian, or Spanish. Nonhuman, in vitro, modeling and pediatric studies or systematic/narrative reviews were excluded. Full-text eligible reports underwent a second screening of the "Materials and Methods" sections to confirm that adult patients with ESRD were included, that cf-PWV was incorporated, and that a pharmacologic intervention was tested. One of the reviewers screened all full-text copies while a second reviewer randomly verified 75% of all reports. Selected reports underwent full-text review by 2 reviewers for final inclusion decision using pre-specified criteria. Subsequently, eligible studies were abstracted by 2 independent reviewers using a piloted and standardized electronic form. All disagreements were resolved by consensus with a third independent reviewer. If data from selected studies were incomplete, we attempted to contact the principal study author.

Extracted Variables {#section25-2054358120906974}
-------------------

Extracted data included the following: (1) study characteristics, design, and methods: title, authors, journal/source/year, language of publication, country, type of study design, study period, publication status, total number of patients, case ascertainment, inclusion/exclusion criteria, single or multicenter study, randomization, allocation, and concealment and blinding methods (where applicable); (2) sample characteristics: age, sex, type of renal replacement therapy, dialysis vintage, comorbidities, duration of follow-up, and type of arterial stiffness instrumentation; (3) interventions and co-interventions: type of pharmacologic therapy, dose, frequency and duration of treatment, type of comparator, and its dose; (4) outcomes: reduction in cf-PWV, decrease in systolic blood pressure (SBP), and side effects associated with the intervention.

Outcomes {#section26-2054358120906974}
--------

The primary outcome was the reduction in cf-PWV associated with the pharmacologic intervention, and secondary outcomes included effects on SBP. Our decision for choosing SBP as a secondary outcome was based on the determinant nature of this parameter on aortic stiffness. We rationalized that measurements of SBP would provide information on its relationship with aortic stiffness. In addition, diastolic blood pressure is not as frequently reported as SBP in these interventional studies. Consequently, by choosing SBP, we expected to minimize the proportion of missing data.

Quality of Evidence {#section27-2054358120906974}
===================

To assess the certainty in the evidence and strength of recommendations for all pharmacologic interventions in this review, 2 reviewers evaluated quality of evidence according to 5 domains of GRADE recommendations.^[@bibr13-2054358120906974]^

Statistical Analyses {#section28-2054358120906974}
--------------------

All studies were synthesized descriptively, and the outcomes were reported as mean differences and their 95% confidence intervals (CIs). For each study arm, we calculated the mean difference (95% CI) between the pre-treatment baseline and the end of treatment. Eligible studies were initially grouped according to the intervention strategy, study design, and completeness of information. After assessment of study quality and completion of descriptive data summary, we investigated the likelihood of combining data (i.e. pooling of individual effect estimates) from several independent studies that addressed the same intervention. Decision for pooling data was based on both clinical and statistical heterogeneity. Clinical heterogeneity included differences on inclusion and exclusion criteria, study design characteristics, methodological quality, patient characteristics at baseline, duration of exposure, doses, dialysis modality, and directionality of effect estimates. Analysis of statistical heterogeneity was accomplished by using forest plots and reported by the I^2^ test. An I^2^ value less than 30% with a non-significant chi-square statistic (*P* \> .10) was suggestive of low statistical heterogeneity. In addition, sensitivity (i.e. study quality) and sub-group (i.e. treatment duration) analyses within each intervention were performed with the purpose of improving the strength of these associations. When appropriate, we estimated pooled mean differences and their 95% CI using the inverse variance method and the random effects model.^[@bibr14-2054358120906974]^ To minimize the "double counting" error in cross-over studies, half of the total number of study participants were allocated to each study arm. Inter-group differences were analyzed using the Cochrane χ^2^ test with *P* ≤ .10. All analyses were performed using RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014, Copenhagen).

Results {#section29-2054358120906974}
=======

Characteristics of Studies {#section30-2054358120906974}
--------------------------

The literature search yielded 6607 citations ([Figure 1](#fig1-2054358120906974){ref-type="fig"}). After completion of full-text review and abstraction, we included 18 studies that reported at least 1 pharmacologic intervention (13 randomized and 5 non-randomized studies). Ten studies were conducted in Europe (4 Denmark, 4 France, 1 Spain, 1 Hungary), 4 in Asia (2 China, 1 Japan, 1 Taiwan), 2 in Australasia (Australia/New Zealand), and 2 in North America (1 Canada, 1 United States). Thirteen publications were single-center studies and 5 involved multiple site participation. Most studies (14 of 18) were published after the year 2000, with 10 reports published after 2009. [Table 1](#table1-2054358120906974){ref-type="table"} summarizes the study characteristics, and [Table 2](#table2-2054358120906974){ref-type="table"} illustrates the cf-PWV recording devices and side effects reported for the intervention and comparator. Among the randomized studies, 3 were cross-over and 10 were parallel randomized trials. Non-randomized studies included 2 cohorts with matched controls and 3 single cohorts with before-and-after measurements. Studies were clustered according to the arterial stiffness mechanism targeted by the intervention into the following categories: (1) management of bone-mineral metabolism disorder (8 studies), (2) control of hypertension (8 studies), (3) correction of anemia (1 study), and (4) reduction of serum homocysteine levels (1 study). For strategies targeting bone mineral metabolism disorder, we identified interventions that involved supplementation with vitamin D analogues (4 studies), calcimimetics (3 studies), and phosphate binders (1 study). For control of hypertension, 3 classes of antihypertensive agents were studied, including renin-angiotensin system (RAS) inhibitors, calcium-channel blockers (CCB), and beta-blockers. Within this interventional category, 5 studies evaluated effects of single antihypertensive drugs compared with placebo or matched controls, while 3 reports involved "head-to-head" comparisons that evaluated 2 different active treatments.

![PRISMA flow chart.\
*Note.* AV = arteriovenous; CKD = chronic kidney disease; PWV = pulse wave velocity.](10.1177_2054358120906974-fig1){#fig1-2054358120906974}

###### 

Characteristics of Studies With Pharmacologic Interventions Included in This Systematic Review.

![](10.1177_2054358120906974-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (reference)                                 Study design               Quality^[a](#table-fn2-2054358120906974){ref-type="table-fn"}^                Intervention (n)                                                                             Comparator (n)                                                                                Age (years) intervention, comparator   Exposure (months)                     Effect size mean difference (95% CI) (m/s)
  -------------------------------------------------- -------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------- --------------------------------------------
  **Vitamin D supplementation**                                                                                                                                                                                                                                                                                                                                                                                                       

  Hewitt et al^[@bibr15-2054358120906974]^           Parallel RCT               Low risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^       Cholecalciferol 50 000 IU/week × 8 weeks + monthly × 4 months\                               Placebo\                                                                                      61 ± 14\                               6                                     −1.20\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           64 ± 14                                                                      (--4.2, 1.8)\
                                                                                                                                                              (n = 21)                                                                                     (n = 24)                                                                                                                                                                   *P* = .43

  Mose et al^[@bibr16-2054358120906974]^             Parallel RCT               Low risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^       Cholecalciferol 3000 IU/day × 6 months\                                                      Placebo\                                                                                      68 ± 9\                                6                                     +0.70\
                                                                                                                                                              HD/PD\                                                                                       HD/PD\                                                                                        67 ± 13                                                                      (--1.7, 3.1)\
                                                                                                                                                              (n = 22)                                                                                     (n = 19)                                                                                                                                                                   *P* = .56

  Marckmann et al^[@bibr17-2054358120906974]^        Parallel RCT               High risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^      Cholecalciferol 40 000 IU/week × 8 weeks\                                                    Placebo\                                                                                      70 ± 13\                               2                                     +0.0\
                                                                                                                                                              HD only\                                                                                     HD only\                                                                                      68 ± 14                                                                      (--2.9, 2.9)\
                                                                                                                                                              (n = 12)                                                                                     (n = 13)                                                                                                                                                                   *P* = .99

  Hansen^[@bibr18-2054358120906974]^                 Randomized cross-over      High risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^      Paricalcitol\                                                                                Alfacalcidol\                                                                                 64 ±16\                                4                                     Paricalcitol: --7.1%\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           64 ± 14                                                                      (--15.9%, 1.7%)\
                                                                                                                                                              (n = 7)                                                                                      (n = 3)                                                                                                                                                                    Alfacalcidol: 17.6%\
                                                                                                                                                                                                                                                                                                                                                                                                                                      (13.7%, 21.5%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                      Difference: *P* = .04

  **Cinacalcet**                                                                                                                                                                                                                                                                                                                                                                                                                      

  Bonet et al^[@bibr19-2054358120906974]^            Before/after               Fair^[c](#table-fn4-2054358120906974){ref-type="table-fn"}^                   Cinacalcet 35 mg (30-60 mg)/day\                                                             Before treatment                                                                              51.3 ± 18                              12                                    −0.7\
                                                                                                                                                              HD\                                                                                                                                                                                                                                                                     (--5.8, 4.4)\
                                                                                                                                                              (n = 21)                                                                                                                                                                                                                                                                *P* = .79

  Chow et al^[@bibr20-2054358120906974]^             Cohort                     Acceptable(+)^[d](#table-fn5-2054358120906974){ref-type="table-fn"}^          Cinacalcet 25-100 mg daily\                                                                  Matched group PD\                                                                             57 ± 10\                               12                                    −0.04\
                                                                                                                                                              PD\                                                                                          (n = 37)                                                                                      60 ± 13                                                                      (--0.86, 0.78)\
                                                                                                                                                              (n = 33)                                                                                                                                                                                                                                                                *P* = .92

  Poulin et al^[@bibr21-2054358120906974]^           Randomized DB cross-over   Unclear risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^   Cinacalcet 30 mg daily × 7 days\                                                             Placebo (for 7 days)\                                                                         68 ± 4                                 1-week × treatment (1-week washout)   −0.00\
                                                                                                                                                              HD\                                                                                          Cross-over                                                                                                                                                                 (--3.5, 3.5)\
                                                                                                                                                              (n = 21)                                                                                                                                                                                                                                                                *P* = .99

  **Phosphate binders**                                                                                                                                                                                                                                                                                                                                                                                                               

  Othmane et al^[@bibr22-2054358120906974]^          Cohort                     Acceptable\                                                                   Sevelamer 2400 mg daily, increased to 4800 mg daily at discretion × 10 months\               Matched controls (by age, sex, dialysis duration, diabetes)\                                  54.7 ± 8.7 54.0 ± 9.3                  10.8 ± 2.3                            −1.8\
                                                                                (+)^[d](#table-fn5-2054358120906974){ref-type="table-fn"}^                    HD\                                                                                          HD\                                                                                                                                                                        (--3.4, --0.15)\
                                                                                                                                                              (n = 13)                                                                                     (n = 13)                                                                                                                                                                   *P* = .042

  **Pharmacologic control of hypertension**                                                                                                                                                                                                                                                                                                                                                                                           

  *RAS inhibitor monotherapy*                                                                                                                                                                                                                                                                                                                                                                                                         

  Pannier et al^[@bibr23-2054358120906974]^          Randomized cross-over      Low risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^       Quinapril 20 mg single dose\                                                                 Placebo\                                                                                      53 ± 12                                172 hours                             At nadir: --1.40\
                                                                                                                                                              HD\                                                                                          Cross-over                                                                                                                                                                 (--4.6, 1.8)\
                                                                                                                                                              (n = 12)                                                                                                                                                                                                                                                                *P* = .39

  Yu et al^[@bibr24-2054358120906974]^               Parallel RCT               Unclear risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^   Ramipril 1.25 mg, 3 times/week × 2 weeks, 2.5 mg 3 times/week, after\                        Placebo\                                                                                      45 ± 13\                               12                                    −0.40\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           48 ± 14                                                                      (--2.31, 1.51)\
                                                                                                                                                              (n = 24)                                                                                     (n = 22)                                                                                                                                                                   *P* = .68

  Peters et al^[@bibr25-2054358120906974]^           Parallel RCT               Low risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^       Irbesartan 150 mg/day × 2 weeks, 300 mg thereafter\                                          Placebo\                                                                                      61 ± 16\                               12                                    0.40\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           62 ±14                                                                       (--0.7, 1.5)\
                                                                                                                                                              (n = 26)                                                                                     (n = 30)                                                                                                                                                                   *P* = .49

  *Calcium-channel blocker monotherapy*                                                                                                                                                                                                                                                                                                                                                                                               

  London et al^[@bibr26-2054358120906974]^           Parallel RCT               Low risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^       Nitrendipine 20 mg/day × 7 weeks, then 20 mg twice × day)\                                   Placebo\                                                                                      57 ± 11\                               4                                     −1.87\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           57 ± 12                                                                      (--3.7, --0.06)\
                                                                                                                                                              (n = 18)                                                                                     (n = 19)                                                                                                                                                                   *P* = .04

  Saito et al^[@bibr27-2054358120906974]^            Cohort                     Unacceptable (0)^[d](#table-fn5-2054358120906974){ref-type="table-fn"}^       Nifedipine 10-20 mg daily\                                                                   Age-matched\                                                                                  52 ± 11\                               24                                    Nifedipine: --2% controls: +10%\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           51 ± 4                                                                       *P* \< .01
                                                                                                                                                              (n = 47)                                                                                     (n = 46)                                                                                                                                                                   

  *Head-to-head trials (antihypertensive classes)*                                                                                                                                                                                                                                                                                                                                                                                    

  London et al^[@bibr28-2054358120906974]^           Parallel RCT               Low risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^       Perindopril 2 mg/day, 3 times/week^[e](#table-fn6-2054358120906974){ref-type="table-fn"}^\   Nitrendipine 20 mg/day 3 times/week^[d](#table-fn5-2054358120906974){ref-type="table-fn"}^\   55 ± 3\                                12                                    −0.33\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           52 ± 5                                                                       (--1.25, 0.59)\
                                                                                                                                                              (n = 14)                                                                                     (n = 10)                                                                                                                                                                   *P* = .48

  Sun et al^[@bibr29-2054358120906974]^              Parallel RCT               High risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^      Losartan 50 mg/day\                                                                          Bisoprolol 5 mg/day\                                                                          57 ± 10\                               12                                    −0.5\
                                                                                                                                                              (n = 33)                                                                                     (n = 32)                                                                                      59 ± 10                                                                      (--0.70, --0.31)\
                                                                                                                                                                                                                                                                                                                                                                                                                                      *P* = .021

  Georgianos et al^[@bibr30-2054358120906974]^       Parallel RCT               High risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^      Atenolol 100 mg maximum)/3 times × week\                                                     Lisinopril 40 mg maximum)/3 times/week\                                                       52 ± 12\                               6                                     −14.8%\
                                                                                                                                                              HD\                                                                                          HD\                                                                                           53 ± 13                                                                      (1.5%, 28.5%)\
                                                                                                                                                              (n = 60)                                                                                     (n = 49)                                                                                                                                                                   *P* = .03

  *Serum homocysteine*                                                                                                                                                                                                                                                                                                                                                                                                                

  Zoungas et al^[@bibr31-2054358120906974]^          Parallel RCT               Unclear risk of bias^[b](#table-fn3-2054358120906974){ref-type="table-fn"}^   Folic acid 15 mg/day\                                                                        Placebo\                                                                                      56 ± 13\                               12                                    −0.31\
                                                                                                                                                              PD, HD, or awaiting dialysis\                                                                PD, HD, or awaiting dialysis\                                                                 56 ± 14                                                                      (--1.20, 0.57)\
                                                                                                                                                              (n = 156)                                                                                    (n = 159)                                                                                                                                                                  *P* = .49

  *Correction of anemia*                                                                                                                                                                                                                                                                                                                                                                                                              

  London et al^[@bibr32-2054358120906974]^           Before/after               Poor^[c](#table-fn4-2054358120906974){ref-type="table-fn"}^                   rec-Human erythropoietin 100 IU/kg IV (repeated 10-35 weeks)\                                Before treatment\                                                                             29 (17-49)\                            8.75                                  1.0\
                                                                                                                                                              (n = 11)                                                                                     HD                                                                                            All patients                                                                 (--1.1, 3.2)\
                                                                                                                                                                                                                                                                                                                                                                                                                                      *P* = .36
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* CI = confidence interval; HD = hemodialysis; PD = peritoneal dialysis; rec = recombinant; RCT = randomized controlled trial.

Although tools for observational studies are specific to the methodological design, they are equivalent to the rating level of grading.^[@bibr8-2054358120906974],[@bibr11-2054358120906974],[@bibr12-2054358120906974]^

The Cochrane Collaboration's tool for assessing risk of bias in randomized controlled trials---Interpretation: *low risk of bias*: plausible bias unlikely to seriously alter the results; *unclear risk of bias*: plausible bias that raises some doubt about the results; *high risk of bias*: plausible bias that seriously weakens confidence in the results.

NIH Quality Assessment Tool for cross-sectional studies and single cohorts before-and-after (called pre-and-post) studies with no control group---Interpretation: *good quality*: minimal risk of bias with a low risk of measurement errors or other confounding factors that would results from "flaws" in the design or conduct of the study (this is equivalent to low risk of bias); *fair quality*: presence of some risk of bias in confounding, selection, information, and measurement derived from several "flaws" in the design or conduct of the study. Also, there is some doubt about the ability of the study to accurately assess an association between the intervention or exposure and outcome; *poor quality*: poor internal validity and high risk for "flaws" in the design and/or execution of the study. There is high doubt about the results reported in the study or the ability of the study to accurately assess an association between the intervention or exposure and the outcome (this is equivalent to high risk of bias).

The SIGN50 tool for assessing methodological quality in cohort studies---Interpretation: *high quality* (++): majority of criteria met, little or no risk of bias, and results unlikely to be changed by further research; *acceptable* (+): most criteria met, some flaws in the study with an associated risk of bias, and conclusions may change in the light of further studies; *low quality* (0) *or unacceptable*: either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to change in the light of further studies.

Double dose if DBP \> 95 mm Hg.

###### 

Aortic Stiffness Recording Devices, Effects on Heart Rate, and Side Effects Associated With Pharmacologic Interventions.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (reference)                             Effects on heart rate                      Recording device cf-PWV                                      Intervention-reported side effects                    Comparator-reported side effects
  ---------------------------------------------- ------------------------------------------ ------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------
  *Cholecalciferol*                                                                                                                                                                                            

  Hewitt et al^[@bibr15-2054358120906974]^       Not reported                               SphygmoCor PVx\                                              Bone fractures = 1\                                   Bone fractures = 0\
                                                                                            (AtCor Medical, Sydney, Australia)                           Serum calcium \>10.4 mg/dL on ≥1 occasion = 3\        Serum calcium \>10.4 mg/dL on ≥1 occasion = 2\
                                                                                                                                                         Serum phosphate \>5.0 mg/dL on ≥1 occasion = 17\      Serum phosphate \>5.0 mg/dL on ≥1 occasion = 20\
                                                                                                                                                         Gastrointestinal events =3\                           Gastrointestinal events = 3\
                                                                                                                                                         Withdrawal due to death =1                            Withdrawal due to death = 1

  Mose et al^[@bibr16-2054358120906974]^         Not reported                               SphygmoCor CPV,\                                             Hypercalcemia = 1\                                    Hypercalcemia = 0\
                                                                                            (AtCor Medical, Sydney Australia)                            Cerebrovascular disease = 1                           Cerebrovascular disease = 2

  Marckmann et al^[@bibr17-2054358120906974]^    Not reported                               Applanation tonometer\                                       Small but significant rise in FGF-23\                 None reported
                                                                                            (Millar, SPT-301B, Houston, Texas)                           Mild to moderate hypercalcemia = 5                    

  Hansen^[@bibr18-2054358120906974]^             Not reported                               SphygmoCor\                                                  Alfacalcidol:\                                        Paricalcidol:\
                                                                                            (AtCor Medical, Sydney Australia)                            Gastrointestinal = 3\                                 Gastrointestinal = 5\
                                                                                                                                                         Dermatologic = 1\                                     Dermatologic = 0\
                                                                                                                                                         Death = 1\                                            Death = 0\
                                                                                                                                                         Respiratory = 1\                                      Respiratory = 1\
                                                                                                                                                         Cardiovascular/stroke = 10\                           Cardiovascular/stroke = 6\
                                                                                                                                                         Musculoskeletal = 1\                                  Musculoskeletal = 2\
                                                                                                                                                         Infectious = 12                                       Infectious = 8

  *Cinacalcet*                                                                                                                                                                                                 

  Bonet et al^[@bibr19-2054358120906974]^        No effect                                  Complior system\                                             Not reported                                          Not reported
                                                                                            (Artech Medical, Paris, France)                                                                                    

  Chow et al^[@bibr20-2054358120906974]^         Not reported                               Complior system\                                             Severe hypocalcemia = 1\                              None reported
                                                                                            (Artech Medical, Paris, France)                              Death = 2                                             

  Poulin et al^[@bibr21-2054358120906974]^       No between-group differences               Complior SP\                                                 Not reported                                          Not reported
                                                                                            (Artech Medical, Paris, France)                                                                                    

  *Phosphate binders (sevelamer)*                                                                                                                                                                              

  Othmane et al^[@bibr22-2054358120906974]^      No differences                             PulsePen device\                                             Not reported                                          Not reported
                                                                                            (DiaTecne, Milan, Italy)                                                                                           

  *RAS inhibitors monotherapy*                                                                                                                                                                                 

  Pannier et al^[@bibr23-2054358120906974]^      Not reported                               Not specified                                                Not reported                                          Not reported

  Yu et al^[@bibr24-2054358120906974]^           No effect with ramipril                    Not specified                                                Severe cough = 2\                                     Traumatic intracranial hemorrhage = 1
                                                                                                                                                         Hypertension = 1                                      

  Peters et al^[@bibr25-2054358120906974]^       No effect with irbesartan                  SphygmocCor\                                                 Diarrhea = 2\                                         Death = 3
                                                                                            (AtCor Medical, Sydney Australia)                            Hypotension = 1\                                      
                                                                                                                                                         Myocardial infarction = 1\                            
                                                                                                                                                         Poor general condition = 1                            

  *Calcium-channel blocker monotherapy*                                                                                                                                                                        

  London et al^[@bibr26-2054358120906974]^       No effect on heart rate                    Transcutaneous Doppler flow                                  Post-dialysis ionized calcium: 1.43 ± 0.07 mmol/L     Post-dialysis ionized calcium: 1.41 ± 0.06 mmol/L

  Saito et al^[@bibr27-2054358120906974]^        Not reported                               PWV 200\                                                     Not reported                                          Not reported
                                                                                            (Fukuda Elect Co, Tokyo)                                                                                           

  *Head-to-head comparisons*                                                                                                                                                                                   

  London et al^[@bibr28-2054358120906974]^       No effect by perindopril or nitrendipine   Transcutaneous Doppler flow/applanation tonometry            Not reported                                          Not reported

  Sun et al^[@bibr29-2054358120906974]^          Decreased with bisoprolol.\                Complior\                                                    Losartan:\                                            Bisoprolol:\
                                                 No changes with losartan                   (Colson, DuPont Medical, France)                             Fasting insulin levels were reduced                   Fasting insulin levels were not reduced

  Georgianos et al^[@bibr30-2054358120906974]^   No between-group differences               Continuous Doppler flow                                      Not reported                                          Not reported

  *Other pharmacologic treatments*                                                                                                                                                                             

  Zoungas et al^[@bibr31-2054358120906974]^      No differences in heart rate               Applanation tonometry\                                       Treatment discontinuation due to adverse events: 6\   Treatment discontinuation due to adverse effects: 2\
                                                                                            (transducers: Millar Mikro-Tip, SPT-301; Houston, TX, USA)   Cobalamin deficiency (\<160 pmol/L): 6                Cobalamin deficiency (\<160 pmol/L) 6

  London et al^[@bibr32-2054358120906974]^       Lower heart rate at end of treatment       Not specified                                                Not reported                                          Not reported
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* cf-PWV = carotid-femoral pulse wave velocity; PWV = pulse wave velocity; RAS = renin-angiotensin system.

Bone Mineral Metabolism Disorder {#section31-2054358120906974}
--------------------------------

### Vitamin D analogues {#section32-2054358120906974}

Three randomized trials^[@bibr15-2054358120906974][@bibr16-2054358120906974]-[@bibr17-2054358120906974]^ (2 low risk; 1 high risk of bias) that included 111 hemodialysis patients assessed the effects of cholecalciferol on cf-PWV and SBP over placebo ([Table 1](#table1-2054358120906974){ref-type="table"}; [Figures 2](#fig2-2054358120906974){ref-type="fig"} and [3](#fig3-2054358120906974){ref-type="fig"}). One additional trial (high-risk bias) compared the effects of paricalcitol (n = 7) versus alfacalcidol (n = 3).^[@bibr18-2054358120906974]^ Treatment duration was 2 to 6 months for cholecalciferol and 4 months for alfacalcidol. The pooled effect estimates indicated that cholecalciferol did not reduce cf-PWV (--0.03 m/s, 95% CI: \[--1.60; 1.53\], *P* = .97) or SBP (+4.5 mm Hg, 95% CI: \[--7.43; 16.47\], *P* = .46) compared with placebo. Statistical heterogeneity was low (I^2^ = 0%) and study quality (cf-PWV: *P* = .97; SBP: *P* = .93) or treatment duration (cf-PWV: *P* = .82) did not modify the overall effect estimates. In contrast, paricalcitol slightly decreased cf-PWV (--7.1%, 95% CI: \[--15.9%; +1.72%\]), while alfacalcidol resulted in an increase (+17.6%, 95% CI: \[+13.7%; +21.5%\]), with the differences between the groups being marginally significant (*P* = .04). There were no significant effects on SBP (paricalcitol: +1.1%, 95% CI: \[--2.0; 13\] vs alfacalcidol: --5.1%, 95% CI: \[--16.3; 6.1\]; *P* \> .05). This study, however, documented a high rate of attrition and was stopped prematurely.

![Forrest plots of the effect estimates on carotid-femoral pulse wave velocity (PWV) from studies focused on vitamin D analogue treatment (cholecalciferol) to improve aortic stiffness compared with placebo in 3 randomized parallel clinical trials. Studies were grouped according to their risk of bias (low vs high).\
*Note.* All cf-PWV values were non-adjusted for mean blood pressure. CI = confidence interval.](10.1177_2054358120906974-fig2){#fig2-2054358120906974}

![Forrest plots of the effect estimates on systolic blood pressure from studies focused on vitamin D analogue treatment (cholecalciferol) to improve aortic stiffness compared with placebo in 3 randomized parallel clinical trials. Studies were grouped according to their risk of bias (low vs high).\
*Note.* All cf-PWV values were non-adjusted for mean blood pressure. CI = confidence interval.](10.1177_2054358120906974-fig3){#fig3-2054358120906974}

### Calcimimetics {#section33-2054358120906974}

Three studies^[@bibr19-2054358120906974][@bibr20-2054358120906974]-[@bibr21-2054358120906974]^ evaluated the effects of cinacalcet on cf-PWV over placebo or standard care, but only 2 studies reported data on SBP.^[@bibr19-2054358120906974],[@bibr21-2054358120906974]^ The studies had different methodological designs (2 cohorts; 1 cross-over), study quality (1 fair; 1 acceptable; 1 unclear risk of bias), treatment duration (1 week, 12 months, and 12 months), time on dialysis, and dialysis modality (peritoneal dialysis: 1 study; hemodialysis: 2 studies). Although cinacalcet decreased serum parathyroid hormone levels, its effects on cf-PWV (--0.05 m/s, 95% CI: \[--0.85; 0.74\]) and SBP (--1.5 mm Hg, 95% CI: \[--22.10, 19.18\]; *P* = .89) were not different from placebo or standard care. The mean differences in cf-PWV for 2 of the studies^[@bibr20-2054358120906974],[@bibr21-2054358120906974]^ were small and less variable (--0.04 m/s, 95% CI: \[--0.86; 0.78\], *P* = .92; --0.00 m/s, 95% CI: \[--3.53; 3.53\], *P* = .96) but larger and more variable (--0.7 m/s, 95% CI: \[--5.80; 4.42\], *P* = .79) for the other.^[@bibr19-2054358120906974]^

### Phosphate binders {#section34-2054358120906974}

In a single study,^[@bibr22-2054358120906974]^ incremental doses of sevelamer for 11 months in hemodialysis patients (n = 13) with serum phosphorus levels above 1.86 mmol/L decreased cf-PWV (--0.83 m/s, 95% CI: \[--2.1; 0.4\], *P* = .21) compared with 13 controls matched for age, sex, diabetes, and dialysis duration (+0.93 m/s, 95% CI: \[--0.15; 2.01\], *P* = .09; sevelamer vs controls: *P* = .042) without any effects on SBP (sevelamer: +1.5 mm Hg, 95% CI: \[--9.5; 12.5\], *P* = .79; controls: +1.8 mm Hg, 95% CI: \[--9.8; 13.4\], *P* = .77; sevelamer vs controls: *P* = .98). Large differences in baseline calcium and phosphorus parameters might have decreased the strength of these associations.

### Control of Hypertension {#section35-2054358120906974}

Eight studies assessed the effects of antihypertensive agents on cf-PWV and SBP in chronic hemodialysis patients. Three randomized trials evaluated monotherapy with RAS inhibitors (quinapril, ramipril, and irbesartan) compared with placebo. Two additional studies (1 randomized) evaluated effects of the CCB nitrendipine and nifedipine versus placebo or age-matched controls. Also, 3 "head-to-head" trials compared the RAS inhibitors losartan, perindopril, or lisinopril versus the CCB nitrendipine, or the beta-blockers atenolol or bisoprolol. These studies had large differences in treatment doses, inclusion criteria, duration of exposure, study design, and quality.

### RAS inhibitors {#section36-2054358120906974}

Pannier et al^[@bibr23-2054358120906974]^ evaluated the acute effects of a single dose of quinapril in 12 hypertensive hemodialysis patients with SBP greater than 160 mm Hg. Both SBP and cf-PWV decreased within the first 4 hours after quinapril administration compared with placebo. The cf-PWV decreased to a maximum of 17% from baseline values (13.2 ± 2.8 m/s; vs 13.6 ± 3.3 m/s) and was maintained for 52 hours after quinapril administration. Yu et al^[@bibr24-2054358120906974]^ randomized escalating doses of ramipril against placebo in 46 normotensive hemodialysis patients with left ventricular hypertrophy. Ramipril decreased cf-PWV (--0.7 m/s, 95% CI: \[--2.4; 0.9\], *P* \< .05) and SBP (--10 mm Hg, 95% CI: \[--28; 7.9\], *P* \< .05) after 12 months of treatment, but the effect of ramipril on cf-PWV was not significantly different to the placebo group (mean difference: --0.40 m/s, 95% CI: \[--2.3; 1.5\] *P* = .68). Peters et al^[@bibr25-2054358120906974]^ randomized treatment with irbesartan or placebo as add-on to standard hypertensive therapy (target SBP: 140 mm Hg) for 1 year in 56 hemodialysis patients and showed a decrease in SBP (--10.0 mm Hg, 95% CI: \[--18.4; --1.7\], *P* = .02) and cf-PWV (--0.8 cm/s, 95% CI: \[--1.5; 0.0\], *P* = .05) with irbesartan, but these effects were not significantly different to the placebo group (irbesartan vs placebo: SBP: *P* = .76; cf-PWV: *P* = .49). The effects on heart rate were also comparable.

### Calcium-channel blockers {#section37-2054358120906974}

London et al^[@bibr26-2054358120906974]^ randomized 40 hypertensive hemodialysis patients to a 4-month treatment with nitrendipine alone or placebo. Nitrendipine significantly reduced cf-PWV (--2.15 m/s, 95% CI: \[--3.6; --0.71\], *P* \< .01) and pre-dialysis supine SBP (--30 mm Hg, 95% CI: \[--45; --15\], *P* \< .01) from baseline, but no effects were observed in the placebo group (cf-PWV: --0.28 m/s, 95% CI: \[--1.58; 1.02\], *P* = .66; SBP: --10 mm Hg, 95% CI: \[--27.3; 7.3\], *P* \> .05). The effect of nitrendipine on cf-PWV was significantly superior to placebo (nitrendipine vs placebo: --1.87 m/s, 95% CI: \[--3.7; --0.06\], *P* = .04). Saito et al^[@bibr27-2054358120906974]^ compared the change in cf-PWV in response to nifedipine administered for 2 years in 47 hypertensive hemodialysis patients against an age-matched control group. At 2 years, cf-PWV decreased by 2% from baseline in the nifedipine group, but it increased 10% in the control group (nifedipine vs controls; *P* \< .01). SBP did not change significantly between the groups. The 2 studies, however, showed large differences in effect estimates, and these were related to different baseline cf-PWV values (13.2 ± 2.3 m/s vs 9.4 ± 2.2 m/s), times of exposure (4 months vs 24 months), risk of bias (low risk vs unacceptable), and study design (randomized vs non-randomized).

### Head-to-head trials {#section38-2054358120906974}

London et al^[@bibr28-2054358120906974]^ randomized hemodialysis patients with left ventricular hypertrophy to 12 months perindopril (n = 14) or nitrendipine (n = 10). Perindopril and nitrendipine induced similar reductions in SBP (--27 mm Hg, 95% CI: \[--32; --22\], *P* \< .001 vs −20 mm Hg, 95% CI: \[--26; --14\], *P* \< .001) and cf-PWV (--2.0 m/s, 95% CI: \[--2.5; --1.5\], *P* \< .001 vs −1.6 m/s, 95% CI: \[--2.6; --0.7\], *P* \< .001) with a decrease in left ventricular hypertrophy only in patients receiving perindopril. Sun et al^[@bibr29-2054358120906974]^ evaluated the effects of losartan (n = 33) against the beta-blocker bisoprolol (n = 32) on cf-PWV and insulin resistance for 12 months. SBP decreased similarly with either losartan or bisoprolol (*P* \> 0.05; --11 mm Hg, 95% CI: \[--16.4; --5.6\] vs −13 mm Hg, 95% CI: \[--18.6; --7.4\]), but reductions in cf-PWV in the losartan group (--0.9 m/s, 95% CI: \[--1.0; --0.8\]) were significantly greater (*P* = .021) than with bisoprolol (--0.4 m/s, 95% CI: \[--0.6; --0.22\]). This difference persisted even after adjustment for age (*P* = .03). In an open-label trial of 109 hemodialysis patients, Georgianos et al^[@bibr30-2054358120906974]^ studied the effects of incremental doses of lisinopril and atenolol, 3 times per week for 6 months, on cf-PWV and SBP (target SBP: \<140 mm Hg). Atenolol induced greater reduction in cf-PWV relative to lisinopril (mean difference: --14.8%, 95% CI: \[1.5; 28.5\], *P* = .03) that persisted after adjustment for age, sex, race, and baseline SBP, but the effect on SBP was not different between the 2 groups (mean difference: --5.7 mm Hg, 95% CI: \[--26.2; 14.8\], *P* = .59).

### Other Pharmacologic Treatments {#section39-2054358120906974}

A single study^[@bibr31-2054358120906974]^ randomized 315 hemodialysis patients to 15 mg folic acid daily or placebo to lower serum homocysteine levels. After 12 months of treatment, plasma total homocysteine was reduced by 19%, but there was no significant reduction in cf-PWV compared with placebo (--0.31 m/s, 95% CI: \[--1.2; 0.6\], *P* = .49). London et al^[@bibr32-2054358120906974]^ evaluated the impact of recombinant human erythropoietin on cf-PWV in 11 anemic hemodialysis patients before and 10 to 35 weeks after initiation of therapy, SBP and cf-PWV did not change significantly between the 2 times of measurement (before: 8.04 ± 2.6 m/s; after: 9.1 ± 2.52 m/s; *P* = .08).

Quality of evidence {#section40-2054358120906974}
-------------------

Quality of evidence for both cf-PWV and SBP across all interventional categories ranged from very low to low except for cholecalciferol trials, where quality was considered moderate. [Table 3](#table3-2054358120906974){ref-type="table"} summarizes these results.

###### 

Quality of Evidence (GRADE Method)^[a](#table-fn9-2054358120906974){ref-type="table-fn"}^ for cf-PWV and SBP Outcomes in ESRD Patients Among Different Interventions.

![](10.1177_2054358120906974-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intervention                                     Study design^[b](#table-fn10-2054358120906974){ref-type="table-fn"}^   Risk of bias^[c](#table-fn11-2054358120906974){ref-type="table-fn"}^   Inconsistency^[c](#table-fn11-2054358120906974){ref-type="table-fn"}^   Indirectness^[c](#table-fn11-2054358120906974){ref-type="table-fn"}^   Imprecision^[c](#table-fn11-2054358120906974){ref-type="table-fn"}^   Publication bias^[c](#table-fn11-2054358120906974){ref-type="table-fn"}^   Upgrading factors^[d](#table-fn12-2054358120906974){ref-type="table-fn"}^   Quality of evidence
  ------------------------------------------------ ---------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------
  *Carotid-femoral pulse wave velocity (cf-PWV)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Cholecalciferol                                  High quality                                                           Not an issue                                                           Not an issue                                                            Not an issue                                                           Serious\                                                              Undetected                                                                 No upgrade                                                                  Moderate quality\
                                                                                                                                                                                                                                                                                                                                                (--1)                                                                                                                                                                                                                        (+++)

  Cinacalcet                                       High quality                                                           Serious risk\                                                          Not an issue                                                            Not an issue                                                           Serious\                                                              Undetected                                                                 No upgrade                                                                  Low quality\
                                                                                                                          (--1)                                                                                                                                                                                                                 (--1)                                                                                                                                                                                                                        (++)

  RAS inhibitors                                   High quality                                                           Serious risk\                                                          Not an issue                                                            Serious\                                                               Serious\                                                              Undetected                                                                 No upgrades                                                                 Very low quality(+)
                                                                                                                          (--1)                                                                                                                                          (--1)                                                                  (--1)                                                                                                                                                                                                                        

  Calcium-channel blockers                         High quality                                                           Serious risk\                                                          Serious\                                                                Not an issue                                                           Serious\                                                              Undetected                                                                 No upgrades                                                                 Very low quality\
                                                                                                                          (--1)                                                                  (--1)                                                                                                                                          (--1)                                                                                                                                                                                                                        (++)

  *Systolic blood pressure (SBP)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Cholecalciferol                                  High quality                                                           Not an issue                                                           Not an issue                                                            Not an issue                                                           Serious\                                                              Undetected                                                                 No upgrade                                                                  Moderate quality\
                                                                                                                                                                                                                                                                                                                                                (--1)                                                                                                                                                                                                                        (+++)

  Cinacalcet                                       High quality                                                           Serious risk\                                                          Not an issue                                                            Not an issue                                                           Serious\                                                              Undetected                                                                 No upgrade                                                                  Low quality\
                                                                                                                          (--1)                                                                                                                                                                                                                 (--1)                                                                                                                                                                                                                        (++)

  RAS inhibitors                                   High quality                                                           Serious risk\                                                          Not an issue                                                            Serious\                                                               Serious\                                                              Undetected                                                                 No upgrades                                                                 Very Low quality(+)
                                                                                                                          (--1)                                                                                                                                          (--1)                                                                  (--1)                                                                                                                                                                                                                        

  Calcium-channel blockers                         High quality                                                           Serious risk\                                                          Serious\                                                                Not an issue                                                           Serious\                                                              Undetected                                                                 No upgrades                                                                 Very low quality\
                                                                                                                          (--1)                                                                  (--1)                                                                                                                                          (--1)                                                                                                                                                                                                                        (+)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RAS = renin-angiotensin system.

GRADE (*Grading* of Recommendations, Assessment, Development, and Evaluations) provides a structured and transparent evaluation of the importance of outcomes regarding interventions or management strategies according to comprehensive criteria for downgrading and upgrading certainty in evidence. GRADE classifies the quality of evidence into one of four levels as follows: *high* (very confident that the true effect lies close to that of the effect estimate); *moderate* (moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); *low* (our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect); *very low* (we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect).

GRADE starts with a baseline rating of HIGH for randomized trials and LOW for non-randomized studies. This baseline rating can then be adjusted (downgraded or upgraded) after considering 8 assessment criteria and making a judgment about quality based on these criteria.^[@bibr33-2054358120906974]^

Reasons to downgrade the evidence: risk of bias, inconsistency, indirectness, imprecision, and publication bias. For these 5 criteria: if no serious concern exists, the quality is not downgraded from the baseline quality (e.g. high for RCTs); if serious concern exists, the evidence is downgraded one level, for example, from high to moderate (--1); if very serious concern exists, the evidence is downgraded 2 levels, for example, from high to low (--2).

Reasons to upgrade the evidence: large magnitude of effect, dose response, or effect of all plausible confounding factors would be to reduce the effect (where an effect is observed) or suggest a spurious effect (when no effect is observed).

Discussion {#section41-2054358120906974}
==========

We analyzed data from 1027 ESRD patients included in 18 studies that evaluated effects of 4 different pharmacologic interventions on cf-PWV. Most studies (89%) focused on 1 of 2 major pharmacologic strategies: improvement in bone mineral metabolism disorder or management of hypertension. Based on very low-to-moderate quality evidence, our findings suggest that treatment of bone mineral metabolism disorder with active vitamin D analogues or cinacalcet does not cause significant reductions in cf-PWV or SBP over placebo or standard care. Sevelamer caused a discrete reduction in cf-PWV over controls, but this effect was confounded by differences in baseline serum parameters. The use of CCB may show an advantage over RAS inhibitors in decreasing cf-PWV, but results were affected by the small number of studies and differences in inclusion criteria, study quality, and deficient control for confounders. Single studies on folic acid and erythropoietin were underpowered and limited by study design and quality.

Bone Mineral Metabolism Disorder {#section42-2054358120906974}
--------------------------------

Hypovitaminosis D is highly prevalent in patients with ESRD and may contribute to cardiovascular risk.^[@bibr34-2054358120906974]^ Vitamin D analogue supplementation in chronic dialysis patients has been associated with improved parameters of bone mineral metabolism,^[@bibr17-2054358120906974]^ reduction in parathyroid hormone levels, and increased survival.^[@bibr35-2054358120906974]^ Because altered bone mineral metabolism increases the risk for vascular calcification and arterial stiffness, cholecalciferol supplementation has been proposed as an intervention to improve cf-PWV. Based on moderate quality evidence, our findings indicate that treatment of chronic dialysis patients with cholecalciferol for 2 to 6 months does not decrease cf-PWV and SBP over placebo. Paricalcitol may have a slight advantage over alfacalcidol, but the results are based on small numbers of patients. Because serum levels of 25(OH)D are expected to achieve optimal levels between 8 and 12 weeks^[@bibr15-2054358120906974]^ after vitamin D supplementation, treatment for 6 months or less with cholecalciferol may not have been sufficiently long to induce reliable changes in cf-PWV. Furthermore, a previous meta-analysis^[@bibr36-2054358120906974]^ showed a benefit of vitamin D supplementation (1-6 months) on cf-PWV over placebo (--0.93 m/s, 95% CI: \[--1.71; --0.15\], *P* = .02) in patients with chronic kidney disease stages 1 to 4, suggesting that once ESRD is reached, arterial stiffness becomes refractory to this intervention.

In pre-clinical studies, calcimimetics (e.g. cinacalcet) decrease parathyroid hormone levels, vascular calcification, and vascular stiffness.^[@bibr37-2054358120906974],[@bibr38-2054358120906974]^ Based on very low quality of evidence, our findings suggest that despite a reduction in parathyroid hormone levels, the effects of cinacalcet on cf-PWV and SBP in ESRD participants were not superior to standard care or placebo. We speculate that the small number of studies, differences in design and quality, dialysis modality, and short follow-up periods may explain the lack of effect of cinacalcet on cf-PWV. An additional consideration is that cinacalcet has minimal impact on the regulation of Klotho levels,^[@bibr39-2054358120906974]^ which may have greater effects on aortic stiffness compared with parathyroid hormone. The effect of cinacalcet may also have been offset by concomitant use of medications with opposite effects on vascular calcification (i.e. calcium-based phosphate binders).^[@bibr20-2054358120906974]^

Treatment of hyperphosphatemia with sevelamer attenuates progression of aortic calcification in hemodialysis patients.^[@bibr40-2054358120906974],[@bibr41-2054358120906974]^ Our review identified a single small cohort study suggesting that sevelamer modestly decreased cf-PWV in hemodialysis patients without affecting SBP. A major limitation, however, was the lack of control for baseline calcium and phosphorus parameters that made these differences less relevant.

Control of Hypertension {#section43-2054358120906974}
-----------------------

In ESRD, arteriosclerosis and vascular calcification are prominent and associated with increased SBP and aortic stiffness.^[@bibr3-2054358120906974]^ Thus, lowering blood pressure with antihypertensive agents reduces cardiovascular morbidity and mortality in chronic dialysis patients.^[@bibr42-2054358120906974]^ RAS inhibitors have been recommended as initial pharmacologic therapy for control of hypertension in ESRD.^[@bibr43-2054358120906974]^ We identified 2 studies^[@bibr24-2054358120906974],[@bibr25-2054358120906974]^ that evaluated the chronic effects of RAS inhibitors on aortic stiffness. While administration of RAS inhibitors decreased cf-PWV and SBP, these effects were not superior to placebo. However, the small sample sizes and the inconsistency of inclusion criteria, dosage, study quality, volume overload assessment, and medication compliance in these studies strongly support the need for additional well-designed trials to address the impact of RAS blockade on arterial stiffness in ESRD.

CCB are non-dialyzable and thereby allow for improved control of hypertension in ESRD without dose adjustment.^[@bibr44-2054358120906974]^ In hypertensive patients without renal disease, CCB reduce carotid intima-media thickness^[@bibr45-2054358120906974],[@bibr46-2054358120906974]^ and aortic stiffness,^[@bibr47-2054358120906974]^ but their effects in ESRD patients are unclear. In our review, we identified 2 studies that evaluated CCB in chronic dialysis patients. These studies indicate that nitrendipine and nifedipine significantly decrease cf-PWV and SBP compared with placebo or age-matched hemodialysis controls ([Supplementary Table S-1](http://journals.sagepub.com/doi/suppl/10.1177/2054358120906974)). Interestingly, nitrendipine was associated with a moderate effect on aortic stiffness (--1.87 m/s), which if effective, may potentially decrease mortality in ESRD patients by approximately 28%.^[@bibr2-2054358120906974]^ Another trial^[@bibr28-2054358120906974]^ that compared perindopril against nitrendipine reported comparable effects on cf-PWV, but the effect sizes and variability were larger compared with other trials (see [Supplementary Table S-1](http://journals.sagepub.com/doi/suppl/10.1177/2054358120906974)).

Overall, clinical studies have postulated several physiologic mechanisms associated with the effects of the different antihypertensive medications on aortic stiffness that range from lowering central aortic blood pressure to an enhancement of endothelial function and vasodilatation and/or reductions in oxidative stress and inflammation that affect arterial compliance.^[@bibr48-2054358120906974]^ Differences among these mechanisms may account for the different effects of these medications on cf-PWV. Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers have a differential effect on central and peripheral blood pressure that may account for the observed amplification of the pulse pressure and potentially lead to a lesser effect on arterial stiffness.^[@bibr49-2054358120906974],[@bibr50-2054358120906974]^ ACE inhibitors, in particular, have been shown to have an additional effect on reducing oxidative stress, inflammation, and improving vasodilation through reduction in angiotensin II, causing smooth muscle relaxation and remodeling of the vessel wall.^[@bibr51-2054358120906974]^ In contrast, dihydropyridine-type CCB not only antagonize the L-type calcium channel but in animal models have been shown to have antioxidant effects.^[@bibr52-2054358120906974]^ Evidence regarding beta-blockers, however, suggests that these agents may be inferior to other antihypertensive drugs^[@bibr53-2054358120906974]^ in reducing aortic stiffness due to their dominant effect on peripheral versus central blood pressure.^[@bibr54-2054358120906974]^

Limitations {#section44-2054358120906974}
-----------

Our rigorous methodology provided an extensive and comprehensive systematic review on existing pharmacologic interventions that target cf-PWV in ESRD patients. We recognize, however, that quality of evidence ranges from very low to moderate, and that despite our efforts to establish associations between changes in cf-PWV and these interventions, the results should be considered hypothesis-generating given the high methodological heterogeneity, low number of trials, small sample sizes, and lack of control for confounders.

In summary, pharmacologic interventions in ESRD are associated with mixed effects on cf-PWV and conclusions are limited by the paucity of studies, small sample sizes, and methodological inconsistencies. Medications that target bone mineral metabolism disorder do not appear to decrease aortic stiffness in ESRD. In contrast, management of hypertension with CCB may reduce aortic stiffness, but the quality of evidence is very low. The effect of RAS inhibitors on cf-PWV is not greater than placebo. Most importantly, in contrast to decreases in aortic stiffness associated with non-pharmacologic interventions in ESRD (kidney transplant, control of extracellular fluid volume, low calcium dialysate, and intradialytic exercise),^[@bibr7-2054358120906974]^ evidence for pharmacologic therapies is insufficient to recommend their routine use for this purpose. Further well-designed studies are needed to confirm these associations and evaluate their impact on cardiovascular outcomes in ESRD.
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